
Croc				U.S. Patent and	Approved for Frademark Offi	use through 04/30/20 ice: U.S. DEPARTME	PTO/SB/21 (05-03) 03. OMB 0651-0031 NT OF COMMERCE	
1 5 7000 Eunder the P	aperwork Reduction Act	of 1995, no per		quired to respond to a collect ation Number	09/854,24		d OMB control number.	
FORM (to be used for all correspondence after initial filing)			Filing Date		May 11, 2		·CA	
			First Named Inventor				V11 1/1	
			Art Unit		Michael Salgaller			
			Examiner Name		Gerald R. Ewoldt			
Total Number of Pages	3		ey Docket Number	020093-0		1600/20		
			<u> </u>	S (Check all that appl	<u> </u>			
Fee Transmittal Form		Drawing(s)		о (олови или врр.	After Allowance Communication to Group			
Fee Attached	Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences			
Response to Restriction Requirement		Petition			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final		Petition to Convert to a Provisional Application			Proprietary Information			
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address			Status Letter			
Extension of Time Request		Terminal Disclaimer			Other Enclosure(s) (please identify below):			
Express Abandonment Request		Request for Refund			Return Postcard			
Information Disclosure Statement		CD, Number of CD(s)						
Certified Copy of Priority Document(s)				The Commissioner is Account 20-1430.	nmissioner is authorized to charge any additional fees to Deposit 20-1430.			
Response to Missing Parts/ Incomplete Application				J				
Response to Missing Parts under 37 CFR 1.52 or 1.53		,						
	SIGI	NATURE O	F APPL	ICANT, ATTORNEY	, OR AGEN	Т		
Firm Townsend and Townsend and Crew LLP								
Individual	Brian W. Poor Reg. No. 32,928							
Signature Fran W. For								
Date July 10, 2003								
		CERTIFIC	ATE OF	TRANSMISSION/M	AILING			
I hereby certify that this co as first class mail in an en	orrespondence is being velope addressed to: C	facsimile trans ommissioner f	mitted to to or Patents,	he USPTO or deposited wi , P.O. Box 1450, Alexandria	th the United Sta, VA 22313-14	tates Postal Service wit 150 on the date shown t	h sufficient postage pelow.	
Typed or printed nam	a							
Signature		in R			Date	July 10, 2003		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Plectin/48
7.2903

Attorney Docket No. 20093-0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Michael Salgaller et al.

Application No.: 09/854,248

Filed: May 11, 2001

For: METHOD TO INCREASE CLASS

1 PRESENTATION OF

EXOGENOUS ANTIGENS BY HUMAN DENDRITIC CELLS

Examiner:

Gerald R. Ewoldt

Art Unit:

1644

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement dated June 10, 2003, which set forth the following groups of claims:

- I. Claims 1-9, drawn to a composition comprising human dendritic cells (DCs), classified in Class 435, subclass 372.
- II. Claims 10-21, drawn to a method for producing a tumor cell inhibiting response comprising administering to a patient DCs, classified in Class 424, subclass 534.
- III. Claims 22-35, drawn to a method for producing a tumor growth inhibiting response comprising administering to a patient activated T cells, classified in Class 424, subclass 93.71.

Applicants elect to prosecute Group II, claims 10-21, with traverse. Applicants reserve the right to file a divisional or related application to the subject matter encompassed by any claim of a non-elected group. Further, the Examiner has requested election of a single

Michael Salgaller *et al.* Serial No. 09/854,248 Page 2

disclosed specific antigen for continued prosecution. The Examiner has suggested election of a specific antigen listed in dependent claim 6. Applicants elect peptide PSM-P1 (SEQ ID NO: 1), an antigenic peptide from the prostate antigen PSMA (prostate specific membrane antigen) recited in claims 5 and 14 (a claim of elected Group II) for continued prosecution. Further, Applicants note that upon an indication of allowability of a generic claim, a reasonable number of additional species will be considered and can also be claimed in the same application as provided by 37 C.F.R. § 141. Claims 10-13 and 16-21 are generic to the elected species. Claim 14 contains the elected species and claim 15 does not read on the elected species of peptide antigen PSM-P1.

Applicants believe all requirements for responding to the request for restriction have been addressed. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the subject application, the Examiner is invited to telephone the undersigned at (206) 467-9600.

Respectfully submitted,

Dated:

By:

Brian W Poor

Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Ph:(206) 467-9600 Fax: (415) 576-0300

SE 5017239 ví